The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The evolving landscape of obesity pharmacotherapy Nature Reviews Drug Discovery Reversible peptide self assembly enables sustained drug delivery with tuneable pharmacokinetics bioRxiv 'Game changing' data: New obesity drugs tied to major weight loss, may reduce CV risk